I shared your post with Dr. Birrer. He noted that Merck has a compassionate release program and suggests that Karen switch to pembrolizumab (Keytruda). Pembrolizumab (Keytruda) is a checkpoint inhibitor, as is nivolumab (Opdivo). Talk to her physician about the compassionate use program at Merck and getting some help with this. Keep in touch.
The GCS Project is dedicated to finding a cure for Gynecological Carcinosarcoma (aka MMMT), providing current scientifically valid information, and offering a place for the community impacted by this cancer to share stories and hope.